Chin‐Chou Wang

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Luis Paz‐Ares, Mikhail Dvorkin, Yuanbin Chen et al. · The Lancet · 2019 · 2.2K citations

Medicine, Oncology, Pharmacology +14

Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

Jonathan W. Goldman, Mikhail Dvorkin, Yuanbin Chen et al. · The Lancet Oncology · 2020 · 687 citations · Full text

Medicine, Oncology, Pharmacology +14

Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial

Yi‐Long Wu, Ying Cheng, Jianying Zhou et al. · The Lancet Respiratory Medicine · 2020 · 258 citations

Medicine, Oncology, Pharmacology +17

ACUTE RESPIRATORY DISTRESS SYNDROME IN SCRUB TYPHUS

Chin‐Chou Wang, Shih‐Feng Liu, Jien-Wei Liu et al. · American Journal of Tropical Medicine and Hygiene · 2007 · 157 citations

Veterinary Medicine, Infectious Diseases, Internal Medicine +12

Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790M+ NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational Trial

Shun Lü, Qiming Wang, Guojun Zhang et al. · Journal of Thoracic Oncology · 2021 · 143 citations · Full text

Medicine, Oncology, Pharmacology +11